Thrombio

ThromBio is a drug discovery company whose mission is to advance the global standard of care for the treatment of stroke using novel anti-thrombotic drugs with unprecedented safety and efficacy. Leadership: ThromBio’s programme is driven by international leaders in drug discovery & development, experimental biomedicine, global clinical trials capability and commercialisation. Our Lead Candidate: TBO-309 TBO-309 represents an Australian drug development success story, that has resulted in a novel antiplatelet compound with truly remarkable properties. Lead Indications: Acute Ischaemic stroke remains the second largest cause of death and disability globally, with 85% of all strokes caused by blood clots that block blood flow to the brain. TBO-309 is currently being trialled in patients in Phase II clinical trials, as an adjunct to thrombolysis (STARS). Publications: ThromBio’s technology is built around state-of-the-art science and technology, published by internationally recognised leaders in the field of drug discovery & and experimental biomedicine. Media: ThromBio’s technology has received global attention for its breakthrough scientific studies. Contact us on social@thrombio.com.au or for more information look at our website.